- Trials with a EudraCT protocol (10,988)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
10,988 result(s) found.
Displaying page 211 of 550.
EudraCT Number: 2004-003840-22 | Sponsor Protocol Number: D6160C00048 | Start Date*: 2005-06-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients wit... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000174-31 | Sponsor Protocol Number: 20030105 | Start Date*: 2005-04-07 |
Sponsor Name:Amgen Inc | ||
Full Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Spl... | ||
Medical condition: Thrombocytopenia in subjects with Immune Thrombocytopenic Purpura (ITP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013795-44 | Sponsor Protocol Number: NCHECR-ENCORE1 | Start Date*: 2012-06-21 | ||||||||||||||||
Sponsor Name:The Kirby Institute (formerly National Centre in HIV Epidemiology and Clinical Research (NCHECR)), University of New Sou | ||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase in... | ||||||||||||||||||
Medical condition: Human Immunodeficiency Virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019526-14 | Sponsor Protocol Number: E7080-G000-206 | Start Date*: 2010-11-01 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | |||||||||||||
Medical condition: American Joint Committee on Cancer unresectable stage III or stage IV melanima and disease progression with subjects not harboring the V600E-BRAF mutation with disease progression following first l... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014387-20 | Sponsor Protocol Number: DORI-PED-1003 | Start Date*: 2009-10-23 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age Protocol DORI-PED-1003;... | |||||||||||||
Medical condition: hospitalized but medically stable infants (term and preterm), <12 weeks CA, who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. a... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018851-88 | Sponsor Protocol Number: IPR/23 | Start Date*: 2010-09-27 | |||||||||||
Sponsor Name:MOLMED | |||||||||||||
Full Title: NGR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS). | |||||||||||||
Medical condition: Locally advanced or metastatic STS patients untreated or previously treated with one or more prior systemic regimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005305-19 | Sponsor Protocol Number: D5130C00030 | Start Date*: 2008-11-17 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Cl... | |||||||||||||
Medical condition: Stable Coronary Artery Disease AZD6140 is under development for the prevention of thrombotic events in patients with non-ST and ST elevation coronary syndromes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002421-31 | Sponsor Protocol Number: P-AD452-022 | Start Date*: 2005-09-16 | |||||||||||
Sponsor Name:Arakis Ltd | |||||||||||||
Full Title: A phase II randomized, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects ... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001580-22 | Sponsor Protocol Number: 062 | Start Date*: 2004-12-21 |
Sponsor Name:MSD SHARP & DOHME GMBH | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sito... | ||
Medical condition: Homozygous Sitosterolemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-005071-42 | Sponsor Protocol Number: CERL080AGB03 | Start Date*: 2005-05-06 |
Sponsor Name:Novartis Pharmaceuticals UK Limited | ||
Full Title: A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL). | ||
Medical condition: Renal transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002530-20 | Sponsor Protocol Number: GWCL0305 | Start Date*: 2005-04-29 |
Sponsor Name:GW Pharma Ltd | ||
Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex in the treratment of subjects with pain due to diabetic neuropathy | ||
Medical condition: Painful diabetic neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000941-12 | Sponsor Protocol Number: BAY 43-9006 / 11718 | Start Date*: 2005-08-18 |
Sponsor Name:Onyx Pharmaceuticals, Inc. | ||
Full Title: Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV... | ||
Medical condition: unresectable, advanced Stage III or Stage IV melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003349-15 | Sponsor Protocol Number: ARPH-CL-03 | Start Date*: 2006-02-07 | |||||||||||
Sponsor Name:Ariston Pharmaceuticals, Inc | |||||||||||||
Full Title: Intranasal Hydroxocobalamin (AST-726) Treatment for Prohylaxis of Migraine: a Placebo-Controlled, Clinical Study | |||||||||||||
Medical condition: Migraine headache with and without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003145-13 | Sponsor Protocol Number: TMC125-C206 | Start Date*: 2006-07-06 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004383-23 | Sponsor Protocol Number: RISSCH4055 | Start Date*: 2005-11-24 |
Sponsor Name:Janssen Cilag Ltd | ||
Full Title: Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperid... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016973-13 | Sponsor Protocol Number: LX1606.1-203-CS | Start Date*: 2010-03-08 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome | |||||||||||||
Medical condition: Symptomatic Carcinoid Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007978-38 | Sponsor Protocol Number: V3381-2DPNP-02 | Start Date*: 2009-02-12 | |||||||||||
Sponsor Name:Vernalis (R & D) Limited | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for Up to 13 Weeks in Patients with Diabetic Peripheral Neuropath... | |||||||||||||
Medical condition: Diabetic Peripheral Neuropathic Pain (DPNP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002678-31 | Sponsor Protocol Number: CA184-007 | Start Date*: 2006-03-20 | |||||||||||
Sponsor Name:BRISTOL-M.SQUIBB | |||||||||||||
Full Title: Randomized, double-blind, placebo controlled phase II study comparing the safety of MDX-010 BMS-734016 administered with or without prophylactic oral budesonide Entocort EC in patients with unr... | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000164-10 | Sponsor Protocol Number: SPD476-112 | Start Date*: 2013-01-04 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005550-35 | Sponsor Protocol Number: CCD-06001AA1-10 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, REPEATED DOSE, THREE-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF TWO DOSES OF CHF 6001 DPI IN SUBJECTS WITH ... | |||||||||||||
Medical condition: COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
